// App-Quantinova.ai

CT248 : A Phase I/IIa first-in-human trial of a novel, potent and selective DNA-PK inhibitor in patients with advanced malignancies

Researchers

Presenter

  • Timothy A. Yap

Principal Investigators

  • Yingxue Chen

  • Lisa H. Butler

  • Si-houy Lao-Sirieix

  • Elaine Cadogan

  • Lenka Oplustil O'Connor

  • Karthick Vishwanathan

  • Younghwa Kim

  • Dnal Landers

  • Emma Dean

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • AstraZeneca, Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Doxorubicin Hydrochloride

  • Olaparib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Adaptive

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • I/II

Study Id's

  • NCT03907969]

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved